Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC

被引：0

作者：

Liu, B. ^{[1
]}

Lisberg, A. ^{[1
]}

Salehi-Rad, R. ^{[1
]}

Lee, J. M. ^{[1
]}

Tran, L. M. ^{[1
]}

Krysan, K. ^{[1
]}

Li, R. ^{[1
]}

Lim, R. J. ^{[1
]}

Dumitras, C. ^{[1
]}

Jing, Z. ^{[1
]}

Abtin, F. ^{[1
]}

Suh, R. D. ^{[1
]}

Genshaft, S. J. ^{[1
]}

Oh, S. ^{[1
]}

Aberle, D. R. ^{[1
]}

Winter, L. E. ^{[1
]}

Sharma, S. ^{[1
]}

Elashoff, D. ^{[1
]}

Garon, E. B. ^{[1
]}

Dubinett, S. M. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A33

引用

页码：S23 / S23

页数：1

共 26 条

[1] Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
Lisberg, A.
Liu, B.
Salehi-Rad, R.
Lee, J.
Tran, L.
Krysan, K.
Li, R.
Lin, Y.
Abtin, F.
Suh, R.
Oh, S.
Aberle, D.
Winter, L.
Wallace, W.
Elashoff, D.
Garon, E.
Sharma, S.
Dubinett, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S346 - S347
[2] Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC
Lisberg, A.
Liu, B.
Salehi-Rad, R.
Lee, J. M.
Tran, L.
Krysan, K.
Li, R.
Lin, Y.
Tseng, A.
Abtin, F.
Suh, R.
Oh, S.
Aberle, D.
Winter, L.
Wallace, W. D.
Elashoff, D.
Garon, E.
Sharma, S.
Dubinett, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S978 - S978
[3] A Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC
Liu, Bin
Garon, Edward B.
Lisberg, Aaron E.
Salehi-Rad, Ramin
Lee, Jay M.
Tran, Linh M.
Krysan, Kostyantyn
Li, Rui
Lim, Raymond J.
Paul, Manash
Lin, Ying
Jing, Zhe
Abtin, Fereidoun
Suh, Robert D.
Oh, Scott
Aberle, Denise R.
Winter, Lauren E.
Wallace, William Dean
Elashoff, David
Sharma, Sherven
Dubinett, Steven M.
CANCER RESEARCH, 2019, 79 (13)
[4] Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
Lisberg, A.
Liu, B.
Salehi-Rad, R.
Lee, J.
Tran, L.
Kostyantyn, K.
Lim, R.
Dumitras, C.
Jing, Z.
Abtin, F.
Suh, R.
Genshaft, S.
Fishbein, G.
Kaul, A.
Kahlon, K.
Ashouri, S.
Goldman, J.
Elashoff, D.
Garon, E.
Dubinett, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1005 - S1006
[5] Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC
Lisberg, A. E.
Liu, B.
Salehi-Rad, R.
Lee, J. M.
Tran, L.
Krysan, K.
Lim, R.
Dumitras, C.
Jiang, Z.
Abtin, F.
Suh, R.
Genshaft, S.
Oh, S.
Fishbein, G. A.
O'Higgins, C. M.
Greenwald, D.
Goldman, J. W.
Elashoff, D.
Garon, E. B.
Dubinett, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1096 - S1097
[6] Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
Lisberg, Aaron Elliott
Liu, Bin
Salehi-Rad, Ramin
Lee, Jay M.
Linh Tran
Krysan, Kostyantyn
Lim, Raymond
Dumitras, Camelia
Jiang, Zhe
Abtin, Fereidoun
Suh, Robert
Genshaft, Scott
Fishbein, Gregory
Kaul, Anita
Kahlon, Kanwarpal
Ashouri, Shay
Goldman, Jonathan Wade
Elashoff, David
Garon, Edward B.
Dubinett, Steven M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
Lisberg, Aaron E.
Bin Liu
Salehi-Rad, Ramin
Lee, Jay M.
Tran, Linh
Krysan, Kostyantyn
Lim, Raymond
Dumitras, Camelia
Jiang, Zhe
Abtin, Fereidoun
Suh, Robert
Genshaft, Scott
Oh, Scott
Fishbein, Gregory A.
O'Higgins, Ciara M.
Ashouri, Shay
Goldman, Jonathan W.
Elashoff, David
Garon, Edward B.
Dubinett, Steven M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] In situ vaccination with CCL21-modified dendritic cells (CCL21-DC) combined with checkpoint blockade in murine models of NSCLC
Lim, Raymond J.
Salehirad, Ramin
Liu, Bin
Li, Rui
Tran, Linh M.
Krysan, Kostyantyn
Ong, Stephanie
Huang, Zi L.
Shackelford, David B.
Sharma, Sherven
Dubinett, Steven M.
CANCER RESEARCH, 2019, 79 (13)
[9] Phase I trial of in situ vaccination with autologous CCL21 gene-modified dendritic cells (CCL21DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)
Liu, Bin
Lisberg, Aaron
Salehi-Rad, Ramin
Lee, Jay
Tran, Linh M.
Krysan, Kostyantyn
Lim, Raymond
Dumitras, Camelia
Jing, Zhe
Oh, Michael
Abtin, Fereidoun
Suh, Robert
Genshaft, Scott
Oh, Scott
Fishbein, Gregory
O'Higgins, Ciara M.
Kaul, Anita
Kahlon, Kanwarpal
Ashouri, Shahryar
Goldman, Jonathan
Elashoff, David
Garon, Edward
Dubinett, Steven
CANCER RESEARCH, 2022, 82 (12)
[10] Phase I trial of intratumoral administration of autologous CCL21 gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections
Liu, Bin
Lisberg, Aaron
Salehi-Rad, Ramin
Oh, Michael
Lee, Jay M.
Tran, Linh M.
Krysan, Kostyantyn
Lim, Raymond J.
Dumitras, Camelia
Jing, Zhe
Abtin, Fereidoun
Suh, Robert D.
Genshaft, Scott J.
Oh, Scott S.
Fishbein, Gregory A.
Kaul, Anita
Kahlon, Kanwarpal S.
Ashouri, Shahryar A.
Goldman, Jonathan W.
Elashoff, David A.
Garon, Edward
Dubinett, Steven M.
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 →